<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="437">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155462</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00868-47</org_study_id>
    <nct_id>NCT05155462</nct_id>
  </id_info>
  <brief_title>Analysis of the Different Strategies for Revascularization of the Lower Limbs by Peripheral Angioplasty</brief_title>
  <official_title>Analysis of the Different Strategies for Revascularization of the Lower Limbs by Peripheral Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Clinical Trial Experts Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral arterial disease (PAD) caused by atherosclerosis causes damage to the arteries&#xD;
      originating in the aorta (descending) from the iliacs to the extremities of the lower limbs.&#xD;
      It causes significant morbidity and mortality. Percutaneous revascularization plays a key&#xD;
      role in the management of these patients. Many percutaneous treatment options have been&#xD;
      developed: arteriectomy, naked stents, active balloons and active stents. Of these, only&#xD;
      paclitaxel-active stents were successful in reducing the rates of restenosis and reoperation&#xD;
      in patients with superficial femoral artery injury.The main objective is to study symptomatic&#xD;
      improvement at 1 year of patients treated with revascularization of the lower limbs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic improvement will be assessed by the evolution of the Leriche and Rutherford classifications before the revascularization procedure and 1 year after the revascularization procedure</measure>
    <time_frame>1 year</time_frame>
    <description>Lerich classification : stage I to IV Rutherford : stage 0 to 6</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Angioplasty</condition>
  <arm_group>
    <arm_group_label>Patient treated for defined symptomatic chronic lower extremity ischemia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One or two phone call</intervention_name>
    <description>Phone call to collect patient data</description>
    <arm_group_label>Patient treated for defined symptomatic chronic lower extremity ischemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient 18 or over, treated for symptomatic chronic ischemia of the lower limbs defined by&#xD;
        Rutherford categories 2-4 and / or Leriche stage greater than 2a&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient treated by the peripheral angioplasty department of Claude Galien Hospital&#xD;
             from January 2010 and with at least 1 year of follow-up after the revascularization&#xD;
             procedure&#xD;
&#xD;
          -  Patient treated for symptomatic chronic ischemia of the lower limbs defined by&#xD;
             Rutherford categories 2-4 and / or Leriche stage greater than 2a&#xD;
&#xD;
          -  Stenosis or restenosis (history of balloon angioplasty, active balloon or bare stent)&#xD;
&#xD;
          -  Degree of stenosis ≥ 50% by angiographic evaluation visual, by CT scan or by Doppler&#xD;
             ultrasound&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient aged 18 or over&#xD;
&#xD;
          -  Patient having been informed and not opposing this research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of myocardial infarction or stroke within 3 months of the&#xD;
             revascularization procedure&#xD;
&#xD;
          -  Unstable angina at the time of the revascularization procedure&#xD;
&#xD;
          -  Sepsis at the time of the revascularization procedure&#xD;
&#xD;
          -  Major under guardianship, curatorship or other legal protection, deprived of liberty&#xD;
             by judicial or administrative decision&#xD;
&#xD;
          -  Hospitalized without consent&#xD;
&#xD;
          -  Pregnant, breastfeeding or parturient woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>0683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé Claude Galien</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry UNTERSEEH, Dr</last_name>
      <phone>06.25.08.79.77</phone>
      <email>t.unterseeh@icps.com.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

